Search the Newsreel

Wells Fargo raises BridgeBio Pharma stock price target on launch outlook

Wells Fargo has increased its price target for BridgeBio Pharma (NASDAQ:BBIO) to $102 from $98, maintaining an Overweight rating due to anticipated near-term launches. Despite an 11% year-to-date gain, the stock is considered slightly overvalued. The firm expects further upside after detailed CARDIO-Transform data …

Enbridge's Profit Just Fell 7%. Here's Why That's Not the Real Story.

Midstream operator Enbridge (NYSE: ENB) reported earnings on July 31, and its stock has tumbled more than 7% since. The reason was obvious. The company's profit margin narrowed because its heavy debt load is weighing on net earnings. Enbridge reported earnings per share (EPS) …

Clearbridge Health Reconstitutes Board Following Director’s Cessation

Noida Toll Bridge Company Ltd is Rated Sell

Quantinno Capital Management LP Purchases 21,464 Shares of BridgeBio Pharma, Inc. $BBIO

Quantinno Capital Management LP significantly increased its stake in BridgeBio Pharma, Inc. by 199.2% in the first quarter, adding 21,464 shares to reach a total of 32,240 shares valued at $2.39 million. This move is part of broader institutional investment, with firms like Janus …

Oxley Bridge Acquisition Ord Shs Class A (OBA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Oxley Bridge Acquisition Ord Shs Class A (OBA), detailing future EPS and revenue growth estimates. It includes current stock information such as market cap, P/E ratio, and recent stock price movements. The forecast section covers expected EPS, …

BridgeBio Pharma Inc (BBIO) (Q2 2026) Earnings Call Highlights: Attruby Surges 211% as Pipeline ...

This article first appeared on GuruFocus. Total Revenues: $243.7 million for Q2 2026, compared to $110.6 million in Q2 2025. Attruby Net Product Revenue: $222.4 million, up from $71.5 million in the same period last year. Royalty Revenue: Increased to $15.4 million from $1.6 …

BridgeBio outlines three launches with first PDUFA set for November 27, 2026 and RECLAIM-HP readout in next 18 months

Earnings Call Insights: BridgeBio Pharma (BBIO) Q2 2026 MANAGEMENT VIEW * CEO Neil Kumar framed Q2 as a turning point, saying, "it feels like we're at T=0 in BridgeBio's next chapter," and tied near-term value creation to Attruby’s next phase, adding, "the combination of …

LandBridge Company LLC Class A Revenue Breakdown – TRADEGATE:D5O

LandBridge Company LLC Class A (TRADEGATE:D5O) reported significant revenue in the last fiscal year, totaling ‪169.51 M‬ EUR. The primary revenue driver was the Surface Use Royalties segment, which generated ‪61.96 M‬ EUR, a substantial increase from the previous year. The United States was …

CRBG Looks 4.5% Undervalued on GF Value™

Corebridge Financial Inc (NYSE: CRBG) appears 4.5% undervalued according to GuruFocus' GF Value™, despite recent insider selling. Morgan Stanley's appointment as book-running manager for a recent offering signals market confidence, while the company offers an attractive and sustainable dividend yield of 2.84% with a …

Insider Selling: Bridgewater Bancshares (NASDAQ:BWB) Director Sells $850,400.00 in Stock

BridgeBio Pharma (NASDAQ:BBIO) Announces Earnings Results

Bridgewater Bancshares (BWB) director Shellberg sells 40,000 common shares at $21.26

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago. These figures are adjusted for non-recurring items. This quarterly …

I Compared Enbridge and Suncor: Here’s My Pick This Year

This article compares two Canadian energy companies, Enbridge (TSX:ENB) and Suncor Energy (TSX:SU), for long-term investors focused on dividends and growth. While Suncor offers a cheaper valuation and potential for appreciation, the author picks Enbridge due to its steadier, utility-like cash flow, higher dividend …

BridgeBio Pharma (NASDAQ: BBIO) grows Q2 2026 revenue but carries heavy debt load

BRIDGEBIO PHARMA ($BBIO) Releases Q2 2026 Earnings

This article first appeared on GuruFocus. Total Revenues: $243.7 million for Q2 2026, compared to $110.6 million in Q2 2025. Attruby Net Product Revenue: $222.4 million, up from $71.5 million in the same period last year. Royalty Revenue: Increased to $15.4 million from $1.6 …

BridgeBio Pharma 2026: Revenue $243.68M, EPS ($0.78) — 10-Q Summary

BridgeBio Pharma reported its 2026 quarterly results, showing a significant increase in revenue to $243.68M from $110.57M in the prior year. Despite the revenue growth, the company recorded a net loss of ($152.22M) and a diluted loss per share of ($0.78), though these figures …

Earnings Flash (BBIO) BridgeBio Pharma, Inc. Reports Q2 Revenue $243.7M, vs. FactSet Est of $220.9M

BridgeBio Pharma, Inc. (BBIO) reported its Q2 revenue of $243.7 million, surpassing the FactSet estimate of $220.9 million. The company's stock, traded on Nasdaq, saw a slight increase of 0.22% on August 10, 2026, with year-to-date growth of 10.69%. BridgeBio Pharma focuses on developing …

BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates

BridgeBio Pharma, Inc. - $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly start and keep patients on Attruby - Attruby is the first ATTR-CM …

Corebridge Financial (CRBG) Is Up 7.6% After Q2 Profit, Capital Returns And Annuity Expansion

Corebridge Financial (CRBG) saw its stock rise 7.6% after reporting a Q2 profit, completing a significant share repurchase program, and declaring a common dividend. The company also expanded its Power Series of Index Annuities to enhance retirement product offerings. These developments reinforce Corebridge's focus …

BridgeBio Pharma earnings up next amid encaleret milestone

BridgeBio Pharma is set to report its second-quarter earnings, with analysts expecting a loss of 60 cents per share on revenues of $222.2 million, driven by strong Attruby sales. Investors are keenly watching the commercial performance and the regulatory progress of encaleret, its experimental …

BridgeBio Pharma: Q2 Earnings Snapshot

BridgeBio Pharma Inc. reported a Q2 loss of $152.2 million, or 78 cents per share, missing analyst expectations of 64 cents per share. Despite the loss, the rare disease drug developer exceeded revenue forecasts, posting $243.7 million against an expected $222.6 million. The company's …

DigitalBridge: Strong Earnings, But The Upside Is Capped (NYSE:DBRG)

Bridgestone (TSE:5108) Posts Strong H1 Results, Is The Rally Already Priced In?

Bridgewater Bancshares (BWB) Stock Fair Value Rises After Analysts Lift Earnings Outlook

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. The fair value estimate for Bridgewater Bancshares has shifted from US$22.13 to US$24.00, pointing to an updated long term price target in the mid US$20s. …

WaterBridge Infrastructure (WBI) Could Be 5% Undervalued On Earnings Guidance And Dividend

Zylox-Tonbridge Schedules Board Meeting to Approve Interim Results

Royal Bank of Canada Acquires 48,445 Shares of Seabridge Gold, Inc. $SA

Corebridge Financial, Inc. $CRBG Shares Bought by Janus Henderson Group PLC

Bridgeline Digital Inc (BLIN) Earnings Forecast: Future EPS & Revenue Growth Estimates

WaterBridge Infrastructure LLC (WBI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Corebridge Financial, Inc. (NYSE:CRBG) Given Average Recommendation of "Moderate Buy" by Analysts

Corebridge Earnings Call: Strong Core, VII Drag

Bridge SaaS Limited (BGE.XA) stock price, news, quote and history

Enbridge Inc. (NYSE:ENB) Stock’s 5.8% Weekly Slide Shifts Focus to Leverage and Pipeline Growth